Cholestatic and Autoimmune Liver Diseases SIG: Bile Acid Signaling and Cholestatic Liver Diseases
Recorded On: 11/08/2019
Already registered?
Sign in now.
Recent approval of the synthetic FXR agonist obeticholic acid for primary biliary cholangitis treatment shows that targeting nuclear receptors in treating liver diseases, particularly cholestatic and autoimmune conditions, has therapeutic potential.
Saul J. Karpen
Keith D. Lindor
Huiping Zhou
Key:
Complete
Next
Failed
Available
Locked
Bile Acid Signaling in Genetic Cholestatic Syndromes
Open to view video.
Open to view video.
Presenter: Saul J. Karpen
Ursodiol: 20 Years of Experience: Where Do We Stand?
Open to view video.
Open to view video.
Presenter: Keith D. Lindor